STOCK TITAN

Eloxx Pharmaceuticals (ELOX) director receives 13,587 stock options grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Eloxx Pharmaceuticals director Nina S. Kjellson received a grant of stock options covering 13,587 shares of Common Stock. The options have an exercise price of $11.00 per share and expire on June 8, 2036. They vest in 24 substantially equal monthly installments over two years, conditioned on her continued service. Following this grant, she holds 13,587 stock options directly, reflecting a compensation-related award rather than an open-market purchase or sale.

Positive

  • None.

Negative

  • None.
Insider Kjellson Nina S
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 13,587 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 13,587 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 13,587 options Stock Option (Right to Buy) grant to director
Exercise price $11.00 per share Stock option strike price for Common Stock
Expiration date June 8, 2036 Option term end date
Shares underlying options 13,587 shares Underlying Common Stock for the option grant
Vesting schedule 24 monthly installments Fully vested on second anniversary of grant date
Total options after grant 13,587 options Total derivative holdings following transaction
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "11.0000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-08T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
vest in 24 substantially equal monthly installments financial
"The stock option will vest in 24 substantially equal monthly installments"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kjellson Nina S

(Last)(First)(Middle)
C/O ELOXX PHARMACEUTICALS, INC.
P.O. BOX 274

(Street)
ARLINGTON MASSACHUSETTS 02476

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Eloxx Pharmaceuticals, Inc. [ ELOX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1106/08/2026A13,587 (1)06/08/2036Common Stock13,587$013,587D
Explanation of Responses:
1. The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.
/s/ Sumit Aggarwal, Attorney-in-Fact06/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Eloxx Pharmaceuticals (ELOX) report for Nina S. Kjellson?

Eloxx reported that director Nina S. Kjellson received a grant of 13,587 stock options. These options give her the right to buy Eloxx Common Stock at a fixed exercise price, representing equity-based compensation rather than an open-market trade.

What are the key terms of Nina S. Kjellson’s Eloxx (ELOX) stock option grant?

The grant covers 13,587 stock options with an exercise price of $11.00 per share, expiring June 8, 2036. The options vest in 24 substantially equal monthly installments over two years, subject to her continued service with the company.

How many Eloxx (ELOX) stock options does Nina S. Kjellson hold after this Form 4?

After this reported transaction, Nina S. Kjellson holds 13,587 stock options directly. This figure reflects the full amount of the new grant, as disclosed, and represents her derivative position from this specific award at the time of the filing.

Is Nina S. Kjellson’s Eloxx (ELOX) option grant an open-market purchase or sale?

No, the filing describes the transaction as a grant or award acquisition of stock options, coded “A.” This indicates a compensation-related award granted by Eloxx, not an open-market purchase or sale of existing shares by the director.

How do the vesting terms affect Nina S. Kjellson’s Eloxx (ELOX) stock options?

The options vest in 24 substantially equal monthly installments, fully vesting on the second anniversary of the grant date. Vesting is conditioned on her continuous service, meaning she gains exercisable rights gradually rather than all at once on the grant date.